Felixvet Expands Xylitol-Free Meloxicam Portfolio for Dogs

Kansas City, Mo. — June 25, 2026 — Felixvet Inc. today announced expanded availability of its FDA-approved Meloxicam Oral Suspension, a prescription non-steroidal anti-inflammatory drug (NSAID) indicated for the control of pain and inflammation associated with osteoarthritis in dogs. Featuring a 100% xylitol-free formulation, Meloxicam Oral Suspension provides veterinarians and pet owners with a trusted treatment option designed specifically for canine patients.

Product Details 

Felixvet Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

“Managing osteoarthritis is an important part of helping dogs maintain comfort, mobility, and quality of life,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re proud to offer a 100% xylitol-free Meloxicam Oral Suspension that provides veterinarians and pet owners with a trusted FDA-approved treatment option while expanding availability across multiple package sizes to meet the needs of practices and patients.”

Osteoarthritis is one of the most common chronic conditions affecting dogs and can significantly impact mobility, activity levels, and overall comfort. Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis and is formulated for convenient oral administration.

Meloxicam Oral Suspension contains 1.5 mg of meloxicam per milliliter and is available in the following bottle sizes:

• 10 mL
• 32 mL
• 100 mL
• 200 mL

The oral suspension should be shaken well before use and administered according to veterinary dosing instructions. The included dosing system helps support accurate measurement, particularly in small dogs.

“Veterinarians and pet owners value products that combine safety, convenience, and flexibility,” added Lauren Landolph. “The addition of multiple bottle sizes and a 100% xylitol-free formulation reflects our commitment to developing practical solutions that support the everyday management of chronic conditions such as osteoarthritis.”

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and pet owners with high-quality treatment options across a broad range of therapeutic categories. The original approval of Meloxicam Oral Suspension was announced in December 2025 and remains an important component of Felixvet’s growing pain management portfolio.

For additional information, please contact info@felixvet.com  

About Felixvet
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners. 

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com